Merck data for COVID-19 pill draw global interest for procurements

seekingalpha2021-10-04

Soon after the promising data disclosed by Merck(NYSE:MRK)for its COVID-19 pill, being developed in partnership with Ridgeback Biotherapeutics, countries, including the U.K. and Malaysia, have shown ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

SanWangtikup
2021-10-04
SanWangtikup
Good
小金钱袋
2021-10-04
小金钱袋
Nice
Stormytw
2021-10-04
Stormytw
Great
- Jiaqiang:
  nice
- shutiing:
  yes
- Burpie:
  ya

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1187370078?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-10-04 15:45","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"1187370078","market":"us","top_or_hot":-1,"title":"Merck data for COVID-19 pill draw global interest for procurements","media":"seekingalpha","content":"<div>\n<p>Soon after the promising data disclosed by Merck(NYSE:MRK)for its COVID-19 pill, being developed in partnership with Ridgeback Biotherapeutics, countries, including the U.K. and Malaysia, have shown ...</p>\n\n<a href=\"https://seekingalpha.com/news/3747414-merck-data-for-covid-19-pill-draw-global-interest-for-procurements\">网页链接</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck data for COVID-19 pill draw global interest for procurements</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck data for COVID-19 pill draw global interest for procurements\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-04 15:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3747414-merck-data-for-covid-19-pill-draw-global-interest-for-procurements><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Soon after the promising data disclosed by Merck(NYSE:MRK)for its COVID-19 pill, being developed in partnership with Ridgeback Biotherapeutics, countries, including the U.K. and Malaysia, have shown ...</p>\n\n<a href=\"https://seekingalpha.com/news/3747414-merck-data-for-covid-19-pill-draw-global-interest-for-procurements\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRK","symbol_name":"默沙东","start_time":0,"source_url":"https://seekingalpha.com/news/3747414-merck-data-for-covid-19-pill-draw-global-interest-for-procurements","article_id":"1187370078","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1187370078","pubTimestamp":1633333522,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Soon after the promising data disclosed by Merck(NYSE:MRK)for its COVID-19 pill, being developed in ","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRK":"默沙东"},"translate_title":"新冠肺炎药丸的默沙东数据吸引全球采购兴趣","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRK":0.9},"content_text":"Soon after the promising data disclosed by Merck(NYSE:MRK)for its COVID-19 pill, being developed in partnership with Ridgeback Biotherapeutics, countries, including the U.K. and Malaysia, have shown willingness to procure the experimental antiviral drug.\nThe chair of Britain's antivirals taskforce, Eddie Gray, hinted at the country’s interest in buying the oral therapy called molnupiravir, which, in a Phase 3 trial involving mild-to-moderate COVID-19 patients, reduced the risk of hospitalization or death by 50%\nHowever, speaking at a briefing after the results were announced on Friday, Gray declined to comment directly on the discussions.\n\"We are involved in looking closely at all of the options available, but we're really not in a position to give out the details around specific conversations at this moment in time,\" Gray was quoted by Reuters, as saying.\nMeanwhile, Merck's vice president for infectious diseases discovery, Daria Hazuda, said: \"We're committed to making this drug rapidly available in the UK.\"\nHowever, Malaysia has confirmed that the country was in talks to procure the experimental therapy.\nHealth Minister, Khairy Jamaluddin said in a tweet that he has already started negotiations for purchases.\n“As we transition to living with COVID, we will be adding new, innovative treatment options to our arsenal in addition to vaccines,” he added.\nOn Friday, Merck (MRK) data for the pill hammered the shares of COVID-19 vaccine makers and manufacturers of intravenous and injectable COVID-19 treatments. In contrast, the shares of other developers of oral COVID-19 treatments rose in solidarity.\nAn effective, convenient oral COVID-19 treatment could generate over $10 billion of annual sales, Reuters reported citing estimates from Jefferies.\nThe U.S. government has a $1.2 billion contract with Merck (MRK) to purchase molnupiravir for slightly over $700 per course.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":820998171,"gmtCreate":1633335845936,"gmtModify":1633335846662,"author":{"id":"4087452914358580","authorId":"4087452914358580","name":"SanWangtikup","avatar":"https://static.tigerbbs.com/c7f061d50a9f915d0ce8e8c879871960","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/820998171","repostId":1187370078,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":820901685,"gmtCreate":1633334891421,"gmtModify":1633334891874,"author":{"id":"4088114426953000","authorId":"4088114426953000","name":"小金钱袋","avatar":"https://static.tigerbbs.com/fcfe810767ab9edba4fd3048d353a712","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/820901685","repostId":1187370078,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":820074275,"gmtCreate":1633333900585,"gmtModify":1633333900881,"author":{"id":"3564008227112773","authorId":"3564008227112773","name":"Stormytw","avatar":"https://static.tigerbbs.com/e52e3d83a9b8426eb631c8696b5c6197","vip":1,"crmLevel":6,"crmLevelSwitch":0},"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/820074275","repostId":1187370078,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6087385,"gmtCreate":1633334045831,"gmtModify":1634722381978,"authorId":3574242390662699,"author":{"id":3574242390662699,"authorId":3574242390662699,"name":"Jiaqiang","avatar":"https://static.tigerbbs.com/7dc0f4640424f6dc0793677877e2dbb1","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":820074275,"type":1,"supId":0,"prevId":0,"content":"nice","text":"nice","html":"nice"},{"id":6087402,"gmtCreate":1633334368565,"gmtModify":1634722380670,"authorId":4087286829505350,"author":{"id":4087286829505350,"authorId":4087286829505350,"name":"shutiing","avatar":"https://static.tigerbbs.com/d9570bb377b17d1dc03714978c63e96c","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":820074275,"type":1,"supId":6087385,"prevId":0,"content":"<u>yes</u>","text":"<u>yes</u>","html":"<u>yes</u>"},{"id":6087407,"gmtCreate":1633334483315,"gmtModify":1634722380235,"authorId":3558104210674958,"author":{"id":3558104210674958,"authorId":3558104210674958,"name":"Burpie","avatar":"https://static.tigerbbs.com/72bc2ab8c2cb82e98e9b523e50a4f9ad","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":820074275,"type":1,"supId":6087385,"prevId":0,"content":"<u>ya</u>","text":"<u>ya</u>","html":"<u>ya</u>"}],"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":46,"commentSize":3,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1187370078"}